SEARCH

SEARCH BY CITATION

References

  • 1
    Ishizaka K, Ishizaka T. Identification of gamma IgE antibodies as a carrier of reaginic activity. J Immunol 1967; 99: 118798.
  • 2
    Johansson SGO, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 1967; 13: 38194.
  • 3
    Ishizaka K, Ishizaka T. Biological function of IgE antibodies and mechanisms of reaginic hypersensitivity. Clin Exp Immunol 1970; 6: 2542.
  • 4
    Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 262332.
  • 5
    Jardieu P. Anti IgE therapy. Curr Opin Immunol 1995; 7: 77982.
  • 6
    Jardieu P, Schoenhoff M, Thomas D, Fox J, Presta L. IgE modulation: potential for anti IgE therapy in asthmatic disease. In: Genetics to Quality of Life of the Optimal Treatment and Management of Asthma, eds ChanezP, BousquetJ, MichelFB, GodardP. Seattle: Hogrefe and Huber 1996: 1937.
  • 7
    Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1997; 9: 80513.
  • 8
    Boushey HA, Fahy JV. Monoclonal anti IgE antibody E25 therapy for asthma. Res Immunol 1998; 149: 18992.
  • 9
    Fick RB. Therapy of allergic pulmonary diseases with anti IgE antibodies. Pediatr Pulmonol Suppl 1999; 18: 1157.
  • 10
    Holgate ST, Corne J, Jardieu P, Fick RB, Heusser CH. Treatment of allergic airways disease with anti IgE. Allergy 1998; 53: 838.
  • 11
    Jardieu PM, Fick RB Jr. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol 1999; 118: 1125.
  • 12
    Patalano F. Injection of anti IgE antibodies will suppress IgE and allergic symptoms. Allergy 1999; 54: 10310.
  • 13
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 18490.
  • 14
    Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, Byrne A, Champain K, Thirlwell J, Cioppa GD, Sandstrom T. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 2539.
  • 15
    Scherrmann JM, Terrien N, Urtizberea M, Pierson P, Denis H, Bourre JM. Immunotoxicotherapy: present status and future trends. J Toxicol Clin Toxicol 1989; 27: 135.
  • 16
    Sabouraud AE, Urtizberea M, Cano NJ, Grandgeorge M, Rouzioux JM, Scherrmann JM. Colchicine-specific Fab fragments alter colchicines disposition in rabbits. J Pharmacol Exp Ther 1992; 260: 12149.
  • 17
    Valentine JL, Owens SM. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther 1996; 278: 71724.
  • 18
    Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharmaceut Sci 2004; 93: 264568.
  • 19
    Meno-Tetang GML, Lowe PJ. On the prediction of the human response: a recycled mechanistic PK/PD approach. Basic Clin Pharmacol Tox 2005; 96: 18292.
  • 20
    US BLA ACM. XOLAIR™, BB IND 5369 Final. Available at http://www.fda.gov/ohrms/dockets/ac/03/briefing/3952B1_01_Genentech-Xolair.pdf (last accessed: 17 October 2006).
  • 21
    Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 25461.
  • 22
    Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995; 34: 1047482.
  • 23
    Junghans RP. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 1997; 16: 2957.
  • 24
    Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969; 13: 1110.
  • 25
    Frazer JK, Capra JD. Immunoglobulins: Structure and function. In: Fundamental Immunology, 4th edn, ed Paul WE, Philadelphia: Lippincott-Raven 1999: 3774.
  • 26
    Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, De Woody K, Feldmann M, Maini RN. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 15218.
  • 27
    Waldmann TA, Iio A, Ogawa M, McIntyre OR, Strober W. The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma. J Immunol 1976; 117: 113944.
  • 28
    Xolair Omalizumab for Subcutaneous Use. Package insert. San Francisco, CA: Genentech, Inc. 2003.
  • 29
    Streeten DHP, Bell DS. Circulating blood volume in chronic fatigue syndrome. J Chronic Fatigue Syndrome 1998; 4:311.
  • 30
    Bill A. Plasma protein dynamics. Albumin and IgG capillary permeability, extravascular movement, and regional blood flow in unanesthetized rabbits. Acta Physiol Scand 1977; 101: 2842.
  • 31
    Juweid M, Strauss HW, Yaoita H, Rubin RH, Fischman AJ. Accumulation of immunoglobulin G at focal sites of inflammation. Eur J Nucl Med 1992; 19: 15965.
  • 32
    Hedger MP, Hettiarachchi S. Measurement of immunoglobulin G levels in adult rat testicular interstitial fluid and serum. J Androl 1994; 15: 58390.